Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
deals
4
×
life sciences
national blog main
san francisco blog main
4
×
boston top stories
clinical trials
investing
national top stories
san francisco top stories
amgen
boston
cancer
cancer drugs
eli lilly
fda
roche
the column group
abbvie
akouos
allergan aesthetics
alzheimer's disease
astellas pharmaceuticals
astrazeneca
athira pharma
attralus
avapritinib
biontech
blueprint medicines
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
california institute for biomedical research
chiesi farmaceutici
cholestatic liver diseases
click therapeutics
cobimetinib
covid-19
cstone pharmaceuticals
What
drug
4
×
medicines
cancer
fda
ipo
acquisitions
affects
americans
approval
approved
biggest
bio
blueprint
build
buy
candidate
ceo
company’s
currently
daniel
date
debut
despite
developing
dyne’s
family
frequency
gilead
hardest
hearing
hit
hottest
hunters
loss
marketing
meds
microbiome
millions
moves
muscle
Language
unset
4
×
Current search:
drug
×
unset
×
" san francisco blog main "
×
deals
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
